|
1. Weitz J, Hirsh J. New Anticoagulant Drugs. CHEST January 2001 vol. 119 no. 1 suppl 95S-107S.
2. Castellone, DD. Anticoagulation: Heparin, Coumadin and Beyond. Advance for Administrators of the Laboratory October 2002, 82-90.
3. Johnson, PH et al. Biochemistry and genetic engineering of hirudin. Seminars in Thrombosis and Haemostasis 15: 320-315 (1989).
4.Nutescu EA, Wittkowsky AK. Direct Thrombin Inhibitors for Anticoagulation. The Annuals of Pharmacotherapy Vol. 38, January 2004, 99-107.
5. Walenga J. (2006) Direct Thrombin Inhibitors & Laboratory Monitoring Issues, Coagulation Symposium, Indianapolis, May 5.
6. Castellone DD, Peerschke EIB. (2006) A chromogenic method for quantitation of direct thrombin inhibitors: A case study, ISTH, abstract, Geneva,
7. Götz N. (2004) The Ecarin Clotting Time, a Universal Method to Quantify Direct Thrombin Inhibitors, Pathophysiol Haemost Thromb 2003/04;33:173-183.
8. http://www.pentapharm.com/sw1326.asp
9. Turpie AGG, Bauer KA, Eriksson BI, and Lassen MR. Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery. Archives of Internal Medicine Vol 162, September 9, 2002, 1833-1840.
10.Package Insert, Arixtra (fondaparinux sodium) 2.5mg injection, Organon sanofi-synthelabo, West Orange, NJ, December 2002
11. Arpino PA, Demirjian Z, VanCott EM. (2005) Use of the Chromogenic Factor X Assay to Predict the INR. Pharmacotherapy 25(2):157-164.
|